DADC
ANIK icon

D.A. Davidson & Co’s Anika Therapeutics ANIK Stock Holding History

D.A. Davidson & Co’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-789
Closed -$42K – 2377
2016
Q2 		$42K Hold
789
– – ﹤0.01% 1479
2016
Q1 		$35K Buy
+789
New +$32K ﹤0.01% 1519

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

D.A. Davidson & Co's ANIK Position: Q3 2016 in Review

D.A. Davidson & Co sold out of Anika Therapeutics (ANIK) in Q3 2016, closing a stake of 789 shares — an estimated $42K sold.

D.A. Davidson & Co first reported a position in ANIK in Q1 2016 and held it in 2 quarters. The position peaked at $42K in Q2 2016. 163 funds tracked by Wall St. Rank hold ANIK as of Q3 2016.

  • D.A. Davidson & Co reported no remaining Anika Therapeutics position as of Q3 2016 after selling out during the quarter.
  • D.A. Davidson & Co sold 789 Anika Therapeutics shares in Q3 2016, an estimated $42K.
  • D.A. Davidson & Co first reported a position in Anika Therapeutics in Q1 2016 and held it in 2 quarters.
  • D.A. Davidson & Co's Anika Therapeutics position peaked at $42K in Q2 2016.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2016.

Based on D.A. Davidson & Co's 13F filing for Q3 2016, filed 14 Nov 2016.